Amyl Therapeutics
Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease.
€8.3MSeries A extension
ParticipantN
Noshaq
Activity from announced rounds
Activity in this selectionSeries A
Noshaq is the Belgian investor identified by its own company list and by Novadip and Standing Ovation announcements.
Recorded funding activity
Its recorded companies include Novadip’s regenerative cell therapies, Amyl’s antibodies against amyloid aggregates and Brenus’ off-the-shelf cancer immunotherapy. These programs pursue different clinical mechanisms and retain separate financing records.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $22.1M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionBrenus Pharma
Develops an off-the-shelf in vivo immunotherapy platform for solid tumors
€11MSeries A
Role not disclosed